tipifarnib has been researched along with Cancer of Stomach in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Egawa, N; Ito, K; Kitagawa, H; Kitajima, Y; Matsufuji, S; Noshiro, H; Okuyama, K; Tanaka, T; Yamada, K | 1 |
1 other study(ies) available for tipifarnib and Cancer of Stomach
| Article | Year |
|---|---|
Antitumor effects of low-dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF-1α-expressing gastric cancer cells.
Topics: Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Quinolones; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases | 2021 |